Patnaik Ronit, Tsai Eugenia
UT Health San Antonio, San Antonio, Texas.
Texas Liver Institute, San Antonio, Texas.
Gastroenterol Hepatol (N Y). 2022 Feb;18(2):85-94.
Hepatitis C virus (HCV) infection is a common indication for liver transplantation. If the patient's HCV is untreated prior to liver transplant, infection of the allograft is nearly universal and can lead to graft failure. The demand for deceased-donor organ transplantation continues to surpass the available supply of donor organs. Waitlist mortality remains an important concern, and several strategies have been enacted to increase organ supply, such as using high-risk donors, including those who are HCV positive. The development of safe and highly effective HCV therapy with direct-acting antiviral agents has revolutionized the management of liver transplant candidates and transplantrecipients. Moreover, thenewer antiviral therapieshave paved the road for use of HCV-viremic organs, effectively expanding the donor pool and changing the landscape of solid organ transplantation. This article reviews the data on HCV treatment prior to and after organ transplantation.
丙型肝炎病毒（HCV）感染是肝移植的常见指征。如果患者在肝移植前未接受HCV治疗，同种异体移植物感染几乎是普遍现象，并且可能导致移植物功能衰竭。对已故供体器官移植的需求持续超过可用的供体器官供应。等待名单上的死亡率仍然是一个重要问题，并且已经制定了多种策略来增加器官供应，例如使用高风险供体，包括HCV阳性者。直接作用抗病毒药物的安全高效HCV治疗的发展彻底改变了肝移植候选者和移植受者的管理方式。此外，更新的抗病毒疗法为使用HCV病毒血症器官铺平了道路，有效扩大了供体库并改变了实体器官移植的局面。本文综述了器官移植前后HCV治疗的数据。
